Learn More
Description
Mode of Action: Inhibits initiation of RNA synthesis by binding to β-subunit of RNA polymerase. It inhibits the assembly of DNA and protein into mature virus particles.
- Treats Tuberculosis and Tuberculosis-related mycobacterial infections
- Widely used as an antipruritic agent in the autoimmune cholestatic liver disease, primary biliary cirrhosis (PBC)
- It has been shown to cause hepatitis
Specifications
Specifications
| Physical Form | Powder |
| Absorbance | λ max (methanol): 237–239, 334–338, 475–479nm |
| Melting Point | 183°C to 188°C (decomposition)(literature) |
| Extinction Coefficient | EmM (max absorbance, phosphate buffer, pH 7.38): 33.20 (237nm); 32.10 (255nm); 27.00 (334nm);15.40 (475nm) (Lit.) |
| Quantity | 250 mg |
| Optical Rotation | [α]D25°=+10.6° (c=0.5% in CDCl3)(Lit.) |
| Solubility Information | Soluble in chloroform (349mg/mL, 25°C), DMSO (∽100mg/mL), ethyl acetate (108mg/mL, 25°C), methanol (16mg/mL, 25°C) tetrahydrofuran. |
| Formula Weight | 822.96 |
Safety and Handling
| Recommended Storage | +4°C |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.